Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 GeneticVariation disease BEFREE Three patients with papillary renal cell carcinoma (PRCC) and MET aberrations had partial responses with durations from 39 to 147 weeks. 30952639 2019
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 Biomarker disease BEFREE In metastatic pRCC with a MET amplification, crizotinib maybe a potential met-inhibitory therapeutic option. 30466410 2018
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 GeneticVariation disease BEFREE Both primary tumors and metastases expressed typical markers of pRCC and carried the same activating MET mutation as the parental tumor. 27715452 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 Biomarker disease BEFREE Results Of 109 patients treated, PRCC was MET driven in 44 (40%) and MET independent in 46 (42%); MET status was unknown in 19 (17%). 28644771 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 SomaticCausalMutation disease ORPHANET Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. 26536169 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 GeneticVariation disease BEFREE Papillary renal cell carcinoma with a somatic mutation in MET in a patient with autosomal dominant polycystic kidney disease. 26718059 2016
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 GeneticVariation disease BEFREE Two PRCC PDX models were identified and MET mutation status and copy number determined. 25779944 2015
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 GeneticVariation disease BEFREE Mutations in the MET oncogene are an essential step into the pathogenesis of hereditary pRCC forms, but they can be found only in a small rate of sporadic cases. 26052049 2015
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 GeneticVariation disease BEFREE Finally, germline mutations of the c-Met gene have been proposed as the first predictor of response to targeted therapies in papillary renal cell carcinoma. 24495452 2015
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 Biomarker disease CTD_human Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. 25401301 2015
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 Biomarker disease BEFREE Overall, this study provides evidence that Chromosome 7 gain drives MET gene copy number increase in PRCC tumors, and appears to subsequently lead to an increase in MET protein overexpression in these tumor cells. 26636767 2015
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 Biomarker disease BEFREE The elucidation of the MET pathway status in types I and II pRCC may help to select patients who are more likely to benefit from MET inhibitors. 24812413 2014
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 GeneticVariation disease BEFREE Activating mutations or amplifications in MET have been described in patients with papillary renal cell carcinoma (PRCC). 23213094 2013
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 Biomarker disease CLINGEN c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations. 18055465 2008
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 Biomarker disease BEFREE The MET oncogene was causally involved in the pathogenesis of a rare tumor, i.e., the papillary renal cell carcinoma, in which activating mutations, either germline or somatic, were identified. 16651428 2006
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 GeneticVariation disease BEFREE Activating mutations affecting the MET receptor tyrosine kinase are present in several types of human cancer, particularly in papillary renal cell carcinoma. 15767811 2005
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 Biomarker disease CLINGEN The MET oncogene drives a genetic programme linking cancer to haemostasis. 15772665 2005
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 Biomarker disease CLINGEN Activating Met mutations produce unique tumor profiles in mice with selective duplication of the mutant allele. 15557554 2004
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 GeneticVariation disease BEFREE Alterations of known genes in PRCC include missense mutations in the MET oncogene (7q31) and rare translocations fusing TFE3 at Xp11.2 with a variety of other loci. 12213728 2002
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 Biomarker disease CLINGEN Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. 10433944 1999
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 Biomarker disease CLINGEN Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. 9140397 1997
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 Biomarker disease CLINGEN Activating mutations for the met tyrosine kinase receptor in human cancer. 9326629 1997
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 Biomarker disease CLINGEN The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. 1917129 1991
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 Biomarker disease HPO
Entrez Id: 4233
Gene Symbol: MET
MET
0.800 CausalMutation disease CGI